Boehringer Ingelheim

This study tested a new medicine called survodutide (BI 456906) to see if it helps people with overweight or obesity and type 2 diabetes lose weight. Over 750 adults received either the drug or a placebo injection once a week for about 76 weeks, along with diet and exercise advic…

This study tested a new medicine called BI 1291583 in 22 adults with cystic fibrosis bronchiectasis, a lung condition that causes coughing and infections. Participants took one tablet daily for 12 weeks, and the study checked if the medicine was safe and well-tolerated. The trial…

This early-stage study tested a new drug called BI 765049, alone or combined with another drug (ezabenlimab), in 21 Asian adults with advanced solid tumors (stomach, colorectal, pancreatic, liver, head and neck, or lung cancer) that have a specific marker called B7-H6. The main g…

This study tested a new medicine called survodutide for weight loss in 274 Japanese adults with obesity and related health problems like diabetes or high blood pressure. Participants received weekly injections of survodutide or a placebo for about 1.5 years, along with diet and e…

This study tested a new medicine called survodutide in 307 Chinese adults with obesity or overweight. Participants received weekly injections of either survodutide or a placebo for about 19 months. The main goals were to see how much weight people lost and if at least 5% of body …

This study tests a medicine called survodutide in adults with overweight or obesity and a liver condition called NASH. Participants receive weekly injections of survodutide or a placebo for about a year, along with diet and exercise advice. The goal is to see if the drug reduces …

This study tested a drug called BI 770371 in 28 people with compensated cirrhosis caused by MASH, a liver disease linked to metabolism. Participants received either the drug or a placebo as an infusion every 3 weeks for 12 weeks. The main goal was to see how well the drug is tole…

This study tested a new cancer drug called brigimadlin (BI 907828) in 266 adults with advanced solid tumors that had spread or stopped responding to standard treatments. The goal was to find a safe dose and see if the drug could shrink tumors. Brigimadlin is an MDM2 inhibitor tak…

This completed study monitored 1200 Japanese patients with chronic heart failure who were prescribed JARDIANCE® (empagliflozin) for the first time. Researchers tracked side effects, deaths, and hospitalizations over the long term to see how the drug performs in everyday use. The …

This study tested a medicine called Avenciguat (BI 685509) in 214 adults with scleroderma, a disease that can cause skin hardening and lung or blood vessel damage. Participants took either the study drug or a placebo three times daily for at least 11 months. Researchers measured …

This study tested a new drug called BI 3706674 in 47 adults with advanced stomach or esophageal cancer that had not responded to prior treatment. The drug is a tablet that blocks growth signals in cancer cells. The main goals were to find a safe dose and see if the drug could shr…

This study tested a new medicine called survodutide (BI 456906) to help people with obesity or overweight lose weight. Over 700 adults without type 2 diabetes received either the drug or a placebo injection once a week for about a year and a half, along with diet and exercise adv…

This study checks whether survodutide, a new weight-loss injection, affects heart rhythm in 110 overweight or obese adults. Participants receive survodutide or placebo for about 30 weeks, with heart tests before and after. The goal is to see if the drug is safe for the heart, not…

This study looked at the long-term safety of a medicine called nintedanib in children and teenagers with a rare lung condition that causes scarring (fibrosing interstitial lung disease). All 54 participants took nintedanib capsules twice a day for at least 1.5 to 3 years. The goa…

This study tested a new cancer pill, brigimadlin, against standard chemo (doxorubicin) in 400 adults with advanced dedifferentiated liposarcoma. Participants took either the pill or received chemo infusions every 3 weeks. The goal was to see which treatment better slowed tumor gr…

This study tested two or three drugs together in adults with advanced solid tumors (cancers that have spread). The main goal was to find the safest dose and see if the combination can shrink tumors. Participants took brigimadlin pills and received ezabenlimab infusions every 3 we…

This study tests an experimental oral drug, BI 1819479, in 322 adults with idiopathic pulmonary fibrosis (IPF). Participants receive one of three doses or a placebo for 6 to 12 months. The main goal is to see if the drug can slow the yearly decline in lung function, measured by b…

This study monitored 425 Japanese patients with chronic fibrosing interstitial lung diseases that are getting worse over time (PF-ILD) who were prescribed Ofev capsules. Researchers tracked side effects, especially liver problems, to see how safe the drug is in everyday use. The …

This early-phase study tests two experimental drugs, BI 765049 and ezabenlimab, in adults with advanced solid tumors like colorectal, lung, and pancreatic cancer. The main goal is to find the highest safe dose of BI 765049 alone and in combination with ezabenlimab. Participants r…

This early-phase trial tested a new immunotherapy drug called BI 754091 in 110 people with advanced solid tumours that had spread or could not be removed surgically. The main goals were to find the safest dose and check for side effects. Researchers also looked for early signs th…

This study tested a new immunotherapy drug, ezabenlimab, combined with other cancer medicines in 211 adults with advanced solid tumors that had spread. The goal was to see if the tumors shrank or disappeared. Participants received different drug combinations, and doctors monitore…

This study tested two experimental drugs (BI 754111 and BI 754091) that help the immune system attack cancer. It included 172 adults with advanced solid tumors, including non-small cell lung cancer that had returned after prior treatment. The first part found the safest dose, and…

This study tested a new medicine, BI 764198, in 67 adults with a kidney disease called FSGS. Participants took different doses of the medicine or a placebo daily for 12 weeks. The goal was to see if the medicine could reduce protein in the urine, a sign of better kidney health. T…

This Phase 3 trial tested whether the oral drug afatinib works better than the standard injected drug methotrexate for people with advanced head and neck cancer that has worsened after platinum chemotherapy. The study enrolled 340 patients and measured how long they lived without…

This study tested a new cancer pill called brigimadlin in 138 adults with a rare type of fat-tissue cancer (dedifferentiated liposarcoma). The pill works by blocking a protein that helps the cancer grow. Participants took the pill once every three weeks, and doctors monitored sid…

This study tested a new medicine called BI 1015550 in 1178 adults with progressive fibrosing interstitial lung diseases (PF-ILDs), a condition where lung tissue scars and worsens over time. Participants took either a low or high dose of the drug or a placebo twice daily for at le…

This early-phase trial tested an experimental drug called ezabenlimab, alone or combined with another drug (BI 754111), in 146 Asian patients with advanced solid tumors. The main goals were to check safety, find the right dose, and see if the combination shrinks tumors in cancers…

This early-stage trial tested an experimental drug called BI 3006337 in 64 adults who are overweight or obese and have fatty liver disease. Participants received weekly injections of either the drug or a placebo for about 4 months. The main goal was to check safety and tolerabili…

This early-stage trial tested the safety and tolerability of a new drug called BI 1015550 (Nerandomilast) in 15 people with idiopathic pulmonary fibrosis (IPF). Participants took either the drug or a placebo twice daily for up to 12 weeks. The study aimed to see if the drug is sa…

This study looked at the long-term safety and effectiveness of the drug spesolimab for adults with hidradenitis suppurativa (HS), a painful skin condition. Participants who had already completed a previous spesolimab trial received injections every two weeks for two years. The go…

This study tested a combination of two experimental drugs (BI 836880 and ezabenlimab) in 252 adults with advanced non-squamous lung cancer and other solid tumors. The first part found the safest dose; the second part checked if the combo could shrink tumors. Participants received…

This study tested whether spesolimab, a drug already approved for another skin condition, can help people with moderate to severe hidradenitis suppurativa (HS), a painful skin disease that causes abscesses and tunnels. 209 adults participated, receiving either spesolimab or a pla…

This study monitored 52 Japanese patients with generalized pustular psoriasis (GPP) who received spesolimab for acute symptoms. Researchers tracked side effects and disease activity in everyday clinical settings, not a controlled lab environment. The goal was to see how well the …

This study looked at the long-term safety of a drug called spesolimab in adults with moderate to severe ulcerative colitis who had already finished earlier trials. Researchers tracked side effects and checked if patients achieved remission over about 6.5 years. The goal was to se…

This large Phase 3 trial tested whether the drug BI 1015550 (nerandomilast) can help people with idiopathic pulmonary fibrosis (IPF), a serious lung disease that causes scarring and makes breathing hard. Over 1,100 adults aged 40 and older took either a low or high dose of the dr…

This Phase 2 trial tested a drug called spesolimab (BI 655130) in 51 adults with moderate to severe atopic dermatitis (eczema). Participants received either the drug or a placebo intravenously. The study measured how much eczema severity changed over 16 weeks using the EASI score…

This study tested whether spesolimab, an anti-inflammatory drug, can reduce painful lumps and abscesses in adults with moderate to severe hidradenitis suppurativa. Fifty-two participants were randomly assigned to receive either spesolimab or a placebo for about 3 months. Doctors …

This program in China gave a single infusion of spesolimab to 39 people with a severe skin condition called generalized pustular psoriasis (GPP) during a flare-up. Participants had no other treatment options available. The goal was to control the flare and monitor for side effect…

This study tested four different doses of an experimental drug (BI 655130) against a placebo in 152 adults with moderate to severe palmoplantar pustulosis (PPP), a skin condition causing painful pus-filled blisters on the palms and soles. The main goal was to see which dose best …

This study tested a new drug called spesolimab in 98 adults with moderate-to-severe ulcerative colitis who did not get better with other biologic treatments. The goal was to see if the drug could safely reduce symptoms and help the colon heal. The trial was completed and looked a…

This study tested a drug called spesolimab in 27 adults with Crohn's disease who also have fistulas near the anus. The drug is given by IV every 4 weeks for 24 weeks. The study had two parts: first, researchers took tissue samples to learn what causes the fistulas; second, they c…

This study tested a drug called spesolimab in 59 people with palmoplantar pustulosis (PPP), a painful skin condition causing pustules and plaques on the palms and soles. Participants received either low or high doses of spesolimab or a placebo for 12 weeks. The goal was to see if…

This phase 2 study tested whether adding spesolimab to standard TNF inhibitor therapy could help heal the gut lining in people with mild-to-moderate ulcerative colitis. Twenty-two adults who still had active disease despite TNF inhibitor treatment received spesolimab or a placebo…

This phase 2 trial tested a drug called spesolimab in 8 adults with moderate to severe ulcerative colitis. The main goal was to understand how the drug works in the body, while also checking for safety and any signs of improvement. Participants received the drug for 12 weeks, and…

This study tested a single dose of spesolimab in 53 people with generalized pustular psoriasis (GPP) experiencing a moderate-to-severe flare. The drug aims to quickly clear skin pustules. Results showed that more patients receiving spesolimab had no visible pustules after one wee…

This study tested three doses of a drug called BI 655064 in 121 people with active lupus nephritis, a kidney complication of lupus. The goal was to see if the drug, given as a shot under the skin, could improve kidney function after one year when added to standard treatments. The…

This early-stage study tested a new drug (BI 836880) alone and with another drug (BI 754091) in 21 Japanese patients with advanced solid tumors. The main goal was to find the safest dose and check for side effects. This is not a cure, but a step toward better controlling advanced…

This early-phase trial tested a new drug called BI 836880 in 24 people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to find the safest dose and check for side effects. Researchers also looked at how the drug moves through the bo…

This early-phase trial tested a new drug called BI 836880 in 29 adults with advanced solid tumors that had not responded to standard treatments. The main goal was to find a safe dose and check for side effects. The study was not designed to cure cancer, but to gather information …

This study tested whether a monthly injection of spesolimab can prevent flare-ups of generalized pustular psoriasis (GPP), a rare and severe skin condition. 123 people aged 12 to 75 with clear or nearly clear skin joined the trial. They received either one of three doses of speso…

This study tested whether a new oral medicine, BI 1569912, can help adults aged 18 to 65 with major depressive disorder. 225 participants were randomly assigned to one of three doses of the drug or a placebo, taken daily for 6 weeks. Researchers measured changes in depression sym…

This study followed 18 people in Spain with idiopathic pulmonary fibrosis (IPF) or other progressive lung scarring who were taking nintedanib (OFEV) and had developed diarrhea. The goal was to see if the diarrhea could be controlled after 12 weeks while staying on the full dose. …

This study tested an experimental drug called BI 1569912 in 243 adults aged 18–65 with major depression that didn't improve with previous treatments. Participants took either a low, medium, or high dose of the drug or a placebo once daily for 6 weeks, while continuing their usual…

This phase 3 trial tested whether iclepertin, a daily tablet, can improve learning and memory in adults with schizophrenia. Over 600 participants took either iclepertin or a placebo for 26 weeks while continuing their usual schizophrenia medication. Researchers measured changes i…

This study tested whether a daily medicine called iclepertin can improve memory and thinking in adults with schizophrenia. Over 600 participants took either iclepertin or a placebo for 26 weeks, while continuing their usual schizophrenia medications. Researchers measured cognitiv…

This study looked at whether atomoxetine, a medication for ADHD, can reduce impulsive behavior in adults aged 18-45 with moderate ADHD. Researchers measured impulsivity using questionnaires after a single dose and after two weeks of daily treatment. The goal was to see if the dru…

This study tested a medicine called iclepertin to see if it improves memory and thinking in adults with schizophrenia. About 620 participants took either iclepertin or a placebo daily for 26 weeks, while continuing their usual schizophrenia medications. Researchers measured chang…

This study looked at how healthy men absorb, break down, and eliminate a single dose of an experimental drug called BI 764198. Twenty-four men took the drug by mouth, and researchers measured the drug and its breakdown products in blood, urine, and stool over several days. The go…

This early-stage trial tested the safety and tolerability of an experimental drug called BI 1569912 in 83 healthy men. Participants received either the drug or a placebo in multiple rising doses, with some also trying a gradual dose increase. The study is complete and focused on …

This completed study looked at the safety of the diabetes drug JARDIANCE (empagliflozin) in 299 Korean adults with chronic kidney disease. Researchers tracked side effects and measured changes in a key kidney health marker (urine albumin-creatinine ratio) after 12 and 24 weeks of…

This study in 8 healthy men aims to understand how the experimental drug BI 1584862 is absorbed, broken down, and eliminated from the body. Participants take a single oral dose with a radioactive tracer and a tiny intravenous dose with a stable isotope. Researchers measure the dr…

This study tested whether a pre-filled syringe and a pre-filled pen deliver the same amount of survodutide into the body. Fifty-six healthy or overweight adults received a single dose of each version in random order. Researchers measured drug levels in the blood to see if the two…

This early-stage trial tested the safety and tolerability of single doses of BI 3000202 tablets in 68 healthy men. It also looked at how taking the tablet with or without food affects the drug's levels in the blood. The study is complete and provides basic information for future …

This study looked at how a common antifungal drug, itraconazole, changes the levels of an experimental drug called BI 1584862 in the blood. Fourteen healthy men took BI 1584862 alone and then again with itraconazole to see if the combination altered drug exposure. The results wil…

This early-phase trial tested the safety and how the body handles a single dose of the experimental drug BI 425809 (iclepertin) in 83 healthy men. Researchers compared different forms (drinking solution vs. tablet) and looked at whether food changes drug absorption. The goal was …

This study looked at how the body handles a drug called BI 1584862 in people with different levels of liver function. 43 adults with mild, moderate, or severe liver problems, plus a group with healthy livers, took a single dose of the drug. Researchers measured drug levels in the…

This study looked at how the experimental drug BI 1569912 is absorbed, broken down, and removed from the body. Eight healthy men took a single oral dose with a radioactive tracer, plus a tiny intravenous dose with a different tracer. The goal was to measure how much of the drug e…

This early-phase trial tested the safety and tolerability of an experimental drug called BI 1569912 in 56 healthy Japanese men. Participants received either single or multiple doses of the drug or a placebo. The study aimed to see how the body processes the drug and if it causes …

This completed phase 1 trial in 18 healthy adults examined how multiple doses of the experimental drug BI 1569912 change the way the body processes three common medications: repaglinide (for diabetes), midazolam (for sedation), and bupropion (for depression or smoking cessation).…

This early-stage trial tested the safety and how the body handles multiple doses of an experimental drug called BI 425809 in 96 healthy young and elderly volunteers. Participants took the drug or a placebo daily for 12 days, and some also compared morning versus evening dosing. T…

This completed Phase 1 trial studied 14 healthy men to see if taking itraconazole (an antifungal) changes how the body absorbs an experimental drug called BI 1815368. Participants received BI 1815368 alone and then again with itraconazole. The goal was to measure drug levels in t…

This completed Phase 1 study tested how the antifungal drug fluconazole changes the levels of the experimental drug BI 425809 in the blood. Fifteen healthy men took a single dose of BI 425809 alone, and later took it while also taking fluconazole daily. The goal was to see if flu…

This study checked whether taking iclepertin (a drug being tested for other conditions) changes how the body handles a common birth control pill. Nineteen healthy women took the birth control pill with and without iclepertin, and researchers measured hormone levels in their blood…

This early-phase study tested the drug Iclepertin (BI 425809) in 25 healthy men to see how much of it reaches the brain and how it affects certain brain chemicals. Participants took multiple doses of the tablet, and researchers measured drug levels in blood and spinal fluid. The …

This study looked at how the experimental drug iclepertin (BI 425809) is processed in people with and without liver problems. 29 adults aged 18-79 took a single dose of the drug. Researchers measured drug levels in the blood and monitored safety to see if liver impairment changes…

This study tested three different tablet versions of the experimental drug BI 425809 (also called Iclepertin) in 18 healthy adults. The goal was to see how the body absorbs each version, not to treat any disease. Participants took a single dose of each tablet on separate days, an…

This study looked at whether taking a new drug called BI 425809 with or without food changes how the body absorbs it. Sixteen healthy adults took the drug once with a meal and once on an empty stomach. The results will help doctors decide the best way to take this medicine in fut…

This completed study in France tracked over 10,000 people with idiopathic pulmonary fibrosis to see how long they continued taking antifibrotic drugs (nintedanib or pirfenidone). The goal was to measure the percentage still on treatment after 30 months and identify factors linked…

This completed Phase 1 study in 14 healthy men tested whether taking multiple doses of itraconazole changes the amount of BI 764198 in the blood after a single dose. Participants took BI 764198 alone and then again with itraconazole to compare drug levels. The goal is to understa…

This early-phase study looked at how the experimental drug BI 425809 (iclepertin) changes the way the body processes four common medications: midazolam, warfarin, omeprazole, and digoxin. Thirteen healthy men took these drugs with and without BI 425809 to see if there were any in…

This completed Phase 1 trial in 14 healthy adults tested whether taking BI 764198 along with metformin changes how much metformin gets into the blood. Participants received both drugs together or metformin alone in a crossover design. The goal was to see if there is a drug intera…

This study looked at how the experimental drug BI 3000202 is processed and removed from the body. In one part, 12 healthy adults took the drug as a liquid, and researchers measured how much came out in urine and stool. In another part, they compared taking a tablet versus getting…

This completed Phase 1 trial enrolled 14 healthy men to see how taking bosentan (a drug for high blood pressure in the lungs) affects the amount of BI 425809 (iclepertin) in the blood. Participants took BI 425809 alone for 10 days, then both drugs together for 14 days. The study …

This early-stage trial tested the safety and how the body handles a single dose of an experimental drug called BI 425809 in 49 healthy Japanese and Chinese men. Participants received either the drug or a placebo, and researchers monitored side effects and drug levels in the blood…

This study looked at how different levels of kidney function affect the way the experimental brain drug iclepertin is processed in the body. 36 adults with and without kidney problems took a single dose of the drug. Researchers measured drug levels in the blood to see if kidney i…

This completed Phase 1 trial enrolled 16 healthy men to see how the antibiotic rifampicin affects the levels of an experimental drug called BI 425809 (iclepertin) in the blood. Participants took BI 425809 alone and then again after several days of rifampicin. The study measured d…

This early-stage study looked at how a new drug called BI 425809 affects the way the body processes another medicine, midazolam. Fifteen healthy men took both drugs to see if BI 425809 changes how quickly midazolam is broken down. The goal was to understand potential drug interac…

This study gave 6 healthy men a single dose of the experimental drug BI 425809 (with a radioactive tracer) to see how it moves through the body. Researchers measured how much of the drug came out in urine and stool, and how fast. The goal was to understand the drug's metabolism a…

This completed phase 1 trial enrolled 6 healthy men to measure how much of the experimental drug BI 425809 reaches the bloodstream when taken as a pill compared to a tiny IV dose. Participants received one 25 mg tablet and later a radioactive microtracer injection. The goal is to…

This early-stage trial tested the safety and how the body processes multiple doses of an investigational drug called BI 3810477. It involved 47 healthy adults aged 18 to 60. The study did not aim to treat any disease, but to gather important safety information for future research…

This completed Phase 1 trial looked at whether multiple doses of Survodutide, a weight-loss drug, change how the body absorbs and processes three common drugs: bupropion (an antidepressant), caffeine, and midazolam (a sedative). Thirty-four otherwise healthy adults with overweigh…

This study looked at how three different forms of the experimental drug BI 456906 are absorbed in the body. Thirty healthy adults each received a single dose of all three versions in random order. The goal was to see if the newer forms work similarly to the original, not to treat…

This completed phase 1 trial enrolled 16 healthy adults to compare two formulations of the drug BI 456906 (Survodutide). Participants received a single injection of each version in random order. Researchers measured how much drug got into the blood and how quickly, to see if the …

This study looks at how a single injection of BI 456906, a drug being developed for obesity and liver disease, behaves in the blood of people with different levels of kidney function. Researchers will compare drug levels in 42 adults with normal kidneys to those with mild, modera…

This completed Phase 1 trial studied how the antifungal drug itraconazole changes the way the body processes an experimental drug called BI 3031185. Fourteen healthy men took a single dose of BI 3031185 with and without multiple doses of itraconazole. The goal was to see if itrac…

This study looks at how two common drugs—rifampicin (an antibiotic) and itraconazole (an antifungal)—affect the levels of a new cancer drug called BI 907828 in the blood. It involves 33 adults with advanced solid tumors who have not responded to previous treatments. Participants …

This early-stage study looked at how a new drug called BI 1291583 is broken down and removed from the body. Eight healthy men took a single dose with a radioactive tracer so researchers could track it in urine and stool. The goal was to understand the drug's metabolism and recove…

This study looked at how the body processes four common drugs (rosuvastatin, digoxin, metformin, and furosemide) in healthy people and those with liver cirrhosis. Researchers measured drug levels in the blood to see if liver disease changes how these medicines are handled. The go…

This study looked at how a new drug, zongertinib, changes the way other common drugs (dabigatran, rosuvastatin, metformin, and furosemide) are processed in the body. It involved 32 healthy men who took these drugs with and without zongertinib. The goal was to measure drug levels …

This completed Phase 1 trial enrolled 15 healthy adults to compare two different formulations of the drug nerandomilast and to see if food affects how the new formulation is absorbed. Participants received single doses in a crossover design. The study focuses on drug levels in th…

This early-stage trial tested a single injection of the experimental drug BI 3006337 in 80 healthy men to see if it is safe and how the body processes it. Participants received either the drug or a placebo, and researchers monitored side effects and drug levels in the blood. Sinc…

This completed Phase 1 trial in 32 healthy adults compared how two different combinations of vicadrostat and empagliflozin are absorbed by the body. It also looked at whether food changes drug levels. Participants received a single dose of each combination in random order. The go…

This study looked at how a new drug called BI 3000202 changes the way the body handles two other medicines: rosuvastatin (for cholesterol) and digoxin (for heart conditions). Fourteen healthy adults took part to help researchers understand if the new drug could affect how these m…

This early-stage study tested a new drug called BI 3006337 in 36 healthy Japanese men to see if it is safe and how the body handles it. Participants received either a single shot or multiple shots over 6 weeks. The goal was to measure side effects and drug levels in the blood, no…

This early-stage trial in 24 healthy adults compares how the body absorbs two different pill versions of the drug BI 1015550 (nerandomilast). It also checks whether taking the new commercial formulation with food changes drug levels. The study is complete and aims to guide future…

This early-stage study looked at how taking multiple doses of an experimental drug (BI 1015550) changes the way the body handles two approved lung medications (nintedanib and pirfenidone). Fourteen healthy men received the drugs in a fixed order, and researchers measured drug lev…

This completed phase 1 trial in 16 healthy men examined whether taking multiple doses of the experimental cancer drug zongertinib changes how the body processes three common drugs: midazolam (a sedative), omeprazole (for heartburn), and repaglinide (for diabetes). Participants re…

This completed Phase 1 trial looked at whether taking multiple doses of the experimental drug BI 1015550 (nerandomilast) changes how the body processes midazolam, a common sedative. Fifteen healthy men aged 18-55 took part. The goal was to see if BI 1015550 affects a key liver en…

This study tested whether two different versions of the drug nerandomilast are processed the same way in the body. 64 healthy adults each took a single dose of both formulations at different times. The goal was to see if the new formulation works just like the one used in later-s…

This study checked if two different pill versions of the drug nerandomilast are absorbed the same way in the body. It involved 64 healthy adults who took a single dose of each version at different times. The goal was to confirm the new version works just like the one used in late…

This completed Phase 1 trial studied how the drug nerandomilast is processed in the bodies of 12 healthy Japanese men after a single dose. Participants took one tablet by mouth after fasting. The goal was to measure drug levels in the blood over time. This early-stage study does …

This completed Phase 1 trial in 18 healthy adults tested whether eating a high-fat, high-calorie meal changes how the body absorbs a single 18 mg dose of Nerandomilast (BI 1015550). Participants took the drug either after fasting overnight or right after a heavy meal, and researc…

This early-stage trial tested a single dose of the experimental drug BI 1015550 in 24 healthy Chinese adults. The goal was to see how the drug moves through the body and whether it is safe. No treatment benefit was expected, as this was a safety and dosing study in healthy volunt…

This study looks at how the drug BI 1015550 is absorbed and processed in the blood of people with mild or moderate liver problems compared to those with healthy livers. About 28 adults took a single dose and had blood samples taken over several days. The goal is to understand if …

This early-stage study looked at how taking the experimental drug BI 1015550 with or without food changes its absorption in the body. Twelve healthy men aged 18 to 55 participated. The goal was to understand the best way to take the drug, not to treat any disease.

This completed Phase 1 trial tested whether taking the antifungal itraconazole changes how the body processes a single dose of the experimental drug BI 1015550 (Nerandomilast). Sixteen healthy men received the drug alone and then again while on a 12-day course of itraconazole. Re…

This completed Phase 1 trial tested whether a single dose of the experimental drug BI 1015550 (nerandomilast) affects the heart's electrical activity in 46 healthy adults. Participants received low and high doses of the drug, a placebo, and an open-label heart-safe drug (moxiflox…

This early-phase trial tested the safety and tolerability of an experimental drug called BI 1015550 in 42 healthy men. Participants received either single or multiple rising doses of the drug. The study aimed to understand how the body processes the drug and to check for side eff…

This study looked at how much of the drug BI 1015550 gets into the blood after taking it by mouth compared to directly into a vein. Eight healthy men took the drug as a pill and also received a tiny radioactive tracer dose. The goal was to understand the drug's absorption and pro…

This study looked at how the drug BI 1015550 is processed in people with and without kidney problems. 26 adults took a single dose, and researchers measured drug levels in their blood. The goal was to see if kidney impairment changes how the drug is absorbed, to guide future dosi…

This early-stage study tested a new drug called BI 1015550 in 16 healthy Japanese men to see if it is safe and how the body processes it. Participants received a single rising dose of the drug or a placebo. The goal was to check for side effects and measure drug levels in the blo…

This early-stage study looked at how healthy men absorb, break down, and eliminate a single dose of the drug BI 1015550 (Nerandomilast). Six participants provided urine and stool samples over several days to measure how much of the drug and its byproducts leave the body. The goal…

This study tested a new drug called BI 3034701 for the first time in humans. It involved 125 healthy men and people with overweight or obesity to see how safe the drug is and how it moves through the body. Participants received either the drug or a placebo as an injection under t…

This study involved 1304 adults with rheumatoid arthritis who had at least two risk factors for interstitial lung disease (ILD), such as being male, a smoker, or over 60. Researchers used CT scans to develop a prediction model that helps doctors decide who should be screened for …

This completed Phase 1 trial in 16 healthy men tested how taking carbamazepine (a strong enzyme inducer) changes the amount of zongertinib in the blood. Participants received a single dose of zongertinib alone, then later took increasing doses of carbamazepine for 18 days followe…

This completed Phase 1 trial enrolled 13 healthy men to compare two oral formulations of the drug BI 1810631. Researchers also tested how taking the drug with food or after multiple doses of the acid-reducer rabeprazole changes its absorption. The goal is to guide future dosing a…

This study followed 158 adults with chronic fibrosing interstitial lung disease (a type of progressive lung scarring) who were starting treatment with nintedanib. Researchers wanted to see if changes in lung function (measured by forced vital capacity) over 52 weeks were linked t…

This study looked at how a new drug, BI 655130, enters the bloodstream when injected in different places (belly or thigh) and in different amounts. 48 healthy adults took part. The goal was to learn about the drug's absorption, not to treat any disease.

This early-phase trial tested the safety and how the body handles a single dose of the drug Spesolimab (BI 655130) in 36 healthy adults. Participants received the drug either as a shot under the skin or through an IV. The main goal was to compare how much drug gets into the blood…

This study looked at how taking bosentan (a drug that can speed up liver breakdown of other drugs) changes the amount of nerandomilast in the blood. Sixteen healthy men took nerandomilast alone and then again after several days of bosentan. The goal was to see if bosentan lowers …

This study looked at how taking multiple doses of carbamazepine changes the way the body processes a single dose of nerandomilast. Sixteen healthy men aged 18 to 55 took part. The goal was to measure drug levels in the blood, not to treat any disease.

This completed Phase 1 trial enrolled 15 healthy men to understand how the experimental drug zongertinib is absorbed, broken down, and eliminated from the body. In one part, participants took a radioactive oral solution so researchers could track the drug in urine and stool. In a…

This completed Phase 1 trial tested whether zongertinib tablets made by two different manufacturers are absorbed the same way in the body. Fifty-six healthy adults took a single dose of each version in random order. The goal was to compare drug levels in the blood to ensure the t…

This study in 16 healthy men tested whether taking the cancer drug zongertinib with a high-fat meal changes how much of the drug gets into the blood. Each participant took one dose on an empty stomach and another after a fatty meal, so researchers could compare. The results will …

This completed Phase 1 trial tested how taking multiple doses of itraconazole, a strong antifungal, changes the amount of the cancer drug zongertinib in the blood of 16 healthy men. The goal was to see if itraconazole increases zongertinib levels, which could require dose adjustm…

This completed Phase 1 trial studied how the antibiotic erythromycin changes the levels of a new drug called BI 1291583 in the body. Twenty healthy adults took both drugs to see if the antibiotic affects how the new drug is processed. The goal was to gather safety and dosing info…

This early-stage trial tested the safety and how the body handles single doses of an experimental drug called BI 706321 in 73 healthy men. The study had two parts: one to check safety and drug levels after increasing doses, and another to compare different pill forms and the effe…

This completed Phase 1 trial in 14 healthy adults tested how the diabetes drug empagliflozin enters the body when taken as a whole tablet or dissolved in water and mixed with food. Researchers measured drug levels in the blood to compare absorption. The study aims to guide how th…

This completed Phase 1 trial studied 14 healthy men to see how itraconazole, a common antifungal, affects the levels of a new experimental drug called BI 706321 in the body. Participants took BI 706321 alone and then again after several days of itraconazole. The goal was to measu…

This completed study looked at how people with and without liver cirrhosis process five common medicines: caffeine, warfarin, omeprazole, metoprolol, and midazolam. Only 4 participants took part, including healthy volunteers and those with mild or moderate cirrhosis. Researchers …